Challenge
Our Global client was an emerging player in oncology with a Phase I asset which had just received FDA breakthrough designation. Despite this, their competitor was 6 months ahead and the client's plans plans did not address their need to pick up the pace!
Lucid was engaged to partner with the cross-functional team to develop and coordinate a launch strategy and plan which provided an accelerated pathway to launch, allowing for strategic scenarios that would be further determined with the availability of data readouts and regulatory decisions to come from both the client's own and the client's competitor's development programmes.
Solution
Lucid developed a 90-day SPRINT methodology to enable rapid development of a fully integrated launch strategy and plan:
- Efficient co-creation model, using frequent and short working sessions, with working drafts created to progress collaboration on strategy with minimal time impact
- Fully developed scenario plans to enable rapid response and plan refinement as critical data emerged
- Use of industry benchmarks to drive momentum in team and demonstrate strategies and behaviours of companies who had achieved success coming from an early second-to-market position
- Clear prioritisation and accountability frameworks adopted to streamline process, retain valued time for strategic collaboration and augment impact
- External insight and validation of strategy through PAG, clinical and payor engagement
Outcome
‘Lucid’s work has had an outstanding impact in 3 months. A tailor-made plan encompassing all areas and that allows us to pivot rapidly; an engaged team who have clear priorities and deliverables and are operating with the necessary pace; and a planning process that the oncology business unit can adopt and apply to future assets and launch planning. I wouldn’t hesitate to recommend Lucid to my colleagues.’
Global Head of Precision Oncology